3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Conditions
Polycystic Ovary Syndrome
14
Breast Neoplasms
11
Prostatic Neoplasms
9
Obesity
7
Insulin Resistance
6
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
4
Colorectal Neoplasms
4
Motor Activity
3
Adenocarcinoma of Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Neoplasms
2
Menstruation Disturbances
2
Lymphoma, Large B-Cell, Diffuse
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Diabetes Mellitus
2
Weight Loss
1
Urothelial Cancer
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Smoldering Multiple Myeloma
1
Rectal Neoplasms
1
Prediabetic State
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Overweight
1
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
1
Non-alcoholic Fatty Liver Disease
1
Interventions
Rituximab
134
Cyclophosphamide
100
Vincristine
53
fludarabine phosphate
50
Prednisone
50
Doxorubicin
49
Etoposide
47
Peripheral Blood Stem Cell Transplantation
38
Mycophenolic Acid
37
Whole-Body Irradiation
35
Tacrolimus
29
Busulfan
27
Lenalidomide
26
Filgrastim
26
Cyclosporine
26
Melphalan
24
Methotrexate
21
Antilymphocyte Serum
21
Gemcitabine
18
ibritumomab tiuxetan
17
Granulocyte Colony-Stimulating Factor
17
Cytarabine
17
Carmustine
16
Radiotherapy
15
fludarabine
14
Carboplatin
14
Bendamustine Hydrochloride
14
pembrolizumab
13
ibrutinib
12
Sirolimus
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Large B-Cell, Diffuse
×
Metformin
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts
NCT02815397
2017-11-17
DLBCL
Rush University Medical Center
Phase 2
Terminated
2 enrolled
3 charts